REVA Medical to Present at Wells Fargo Securities 2013 Healthcare Conference

        Print
| Source: REVA Medical, Inc.

SAN DIEGO, June 13, 2013 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and CEO, Robert Stockman, is presenting at the Wells Fargo Securities 2013 Healthcare Conference at 1:50 p.m. US EDT on Wednesday, June 19, 2013. The conference is being held June 18th and 19th at the InterContinental Hotel in Boston, Massachusetts.

The information contained in the presentation has been previously disclosed. A copy of the presentation will be posted under the Investor Relations section of REVA's website at www.revamedical.com shortly before the presentation.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. The ReZolve® product family, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. REVA's anticipated commercial product, the ReZolve2 scaffold, is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve2 scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve2 scaffold.

United States

Investor and Media Enquiries:
Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045

Australia

Investor Enquiries:
Kim Jacobs
Inteq Limited
+61 2 9229 2700

Media Enquiries:
Haley Price or Rebecca Wilson
Buchan Consulting
+61 3 9866 4722